NCT00483496 - Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Idiopathic Solar Urticaria

Interventions

DRUG

Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)

DRUG

Ti02 pigmentary 3% alone (formula RV3131A-MV1211)

DRUG

bisoctrizole 10% alone (formula RV3131A-MV1237)

DRUG

Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)

DRUG

Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)

DRUG

Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)

DRUG

Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]

DRUG

V0096 CR vehicle (formula RV3131A-MV1197)

Trial Locations (3)

St Luke's Roosevelt Hospital Center, New York

Henry Ford Medical Center, Detroit

Ninewells Hospital, Dundee